Detailed analysis of the adverse reactions and treatment methods of Pimitespib

Pimitespib (trade name TAS-116) is a new oral HSP90 (heat shock protein 90) inhibitor, mainly used to treat malignant tumors such as advanced gastric cancer, colorectal cancer, and GIST (gastrointestinal stromal tumor). HSP90 is a molecular chaperone protein that plays a key role in a variety of oncogenic signaling pathways. Inhibiting HSP90 can destroy tumor cell protein homeostasis, thereby inhibiting tumor growth. However, although pimetibi has shown good clinical efficacy and tolerability, like other targeted drugs, a series of adverse reactions may still occur during its use, which requires clinicians and patients to pay close attention and handle them in a timely manner.

Clinical trials and real-world usage data show that the adverse reactions of pimetibib are mainly concentrated in gastrointestinal reactions, skin symptoms, abnormal liver function and eye discomfort. Gastrointestinal adverse reactions are the most common, among which diarrhea, nausea, vomiting and loss of appetite are the most prominent. About 50% to 60% of patients experience varying degrees of diarrhea. Most patients have mild symptoms and are grade 1 to 2 adverse reactions, but if not treated in time, they may lead to dehydration and electrolyte imbalance. Followed by skin-related reactions, such as rash, hand-foot syndrome and pigmentation, the incidence rate is around 20%. In addition, some patients will develop mild to moderate liver function abnormalities, manifested as elevated transaminases (ALT, AST), and a few patients are accompanied by elevated bilirubin. It is worth noting that in a few cases, pimetibib can also cause eye discomfort, including dry eyes, blurred vision, eye pain, etc., suggesting that it is related to the impact of the HSP90 inhibitory mechanism on the lens and optic nerve.

The adverse reactions caused by pimetibib are closely related to its pharmacological mechanism. HSP90It is widely present in normal cells and is involved in protein folding and maintenance of cell homeostasis. While drugs inhibit tumor cellsHSP90, they also interfere with the physiological functions of some normal tissues. For example, gastrointestinal epithelial cells renew quickly and are more sensitive to HSP90 inhibition, so diarrhea and nausea are more common; and the liver, as the main organ of drug metabolism, is prone to mild liver damage when exposed to high concentrations of drugs. Skin reactions are related to the inhibition of keratinocytes and delayed epidermal repair. Adverse eye reactions may be due to the drug affecting the activity of metabolic enzymes in the eye, resulting in lens metabolism disorder or mild damage to retinal nerve cells. Understanding these mechanisms can help doctors better develop prevention and management measures to reduce the incidence and severity of adverse reactions.

Individualized management strategies should be adopted for the adverse reactions of pimetibib. For diarrhea, it is recommended that patients take antidiarrheal drugs (such as loperamide) as soon as symptoms occur, and supplement sufficient water and electrolytes; if diarrhea persists or is severe, temporary discontinuation of the drug or reduction of the dose may be considered. Nausea and vomiting can be prevented early in treatment with antiemetics (such as ondansetron). For skin rashes and hand-foot syndrome, external moisturizers and corticosteroid ointments can be used to avoid friction and high temperature stimulation; if severe skin damage occurs, medication should be suspended and symptomatic treatment should be carried out. People with abnormal liver function should regularly monitor liver function indicators. If ALT/AST rises more than 3 times the normal upper limit, the dose needs to be reduced or the drug discontinued. For patients with eye discomfort, they should avoid prolonged use of their eyes, use artificial tears if necessary or discontinue the medication for a short period, and have their vision changes evaluated by an ophthalmologist.

In clinical management, doctors should inform patients of possible adverse reactions before treatment and conduct basic examinations, such as liver and kidney function, ophthalmological evaluation, etc. Regular follow-up is required during the treatment process to detect signs of adverse reactions in a timely manner. For elderly patients or those with multiple underlying diseases, special attention should be paid to dose adjustment and drug interactions. Patients themselves should also actively cooperate with treatment, pay attention to a light diet, maintain a good daily routine, and avoid drinking alcohol and other hepatotoxic drugs. If you experience persistent discomfort, you should promptly report it to your doctor instead of stopping the medication or adjusting the dose yourself. Generally speaking, the adverse reactions of pimetibib are mostly controllable and reversible. With reasonable management, most patients can continue treatment and obtain stable therapeutic effects.

Pimetibib, as one of the representative drugs ofHSP90 inhibitors, has demonstrated remarkable efficacy in the treatment of a variety of refractory tumors. Although there is a certain risk of adverse reactions during use, the overall safety is relatively controllable. Through scientific monitoring and timely treatment, most patients can safely complete the treatment cycle and maintain a good quality of life. In the future, with the accumulation of more clinical experience and the optimization of adjuvant drug strategies, pimetibi is expected to become one of the important choices for the treatment of various tumors.

Reference materials:https://www.drugs.com/